Comparative study of tegafur gimeracil and oteracil potassium (TS-1) plus docetaxel and oxaliplatin versus TS-1 plus oxaliplatin in postoperative adjuvant chemotherapy for gastric cancer

Objective: The objective of this study was to comparatively study the effect of tegafur gimeracil and oteracil potassium (TS-1) plus docetaxel and oxaliplatin versus TS-1 plus oxaliplatin in postoperative adjuvant chemotherapy for gastric cancer. Methods: A total of 121 advanced patients received chemotherapy after radical gastrectomy were enrolled in this study and randomly assigned to two groups. Sixty-three patients received the chemotherapy regimen of TS-1 plus oxaliplatin and docetaxel were in observation group, while 58 patients received the regimen of TS-1 plus oxaliplatin were in control group. The short-term efficacy, long-term efficacy, Karnofsky performance status (KPS) score and toxic side effects were observed in both groups. Results: The total effective rate was 58.73%, and the total control rate was 87.30% in the observation group, which were significantly higher than those in the control group (39.66% and 72.41%), with statistical differences (both P<0.05). The progression-free survival and overall survival of the observation group were 5.73 and 11.18 months, respectively, which were not statistically significant from those of the control group (5.69 and 11.25 months; both P>0.05). The KPS scores of the observation group were higher than those of the control group after 3-week and 6-week chemotherapy (both P<0.05). There was no significant difference in the adverse reactions between the two groups after chemotherapy (P>0.05). Conclusions: The chemotherapy regimen of TS-1 plus docetaxel and oxaliplatin has significant effects in patients after gastrectomy, and improves patients' physical condition with reliable safety.